RIGEL PHARMACEUTICALS INC (RIGL)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 101,685 | 53,333 | 55,307 | 36,841 |
| Selling, general and administrative | 29,257 | 27,715 | 27,043 | 28,047 |
| Research and development | 6,821 | 8,436 | 6,182 | 5,540 |
| Cost of product sales | 4,504 | 4,409 | 8,026 | 2,807 |
| Total costs and expenses | 40,582 | 40,560 | 41,251 | 36,394 |
| Income (loss) from operations | 61,103 | 12,773 | 14,056 | 447 |
| Interest income | 753 | 591 | 425 | 552 |
| Interest expense | 1,874 | 1,853 | 2,060 | 2,029 |
| Income (loss) before income taxes | 59,982 | 11,511 | - | - |
| Provision for income taxes | 369 | 65 | - | - |
| Net income (loss) | 59,613 | 11,446 | 12,421 | -1,030 |
| Earnings per share, basic | 3.33 | 0.64 | 0.71 | -0.06 |
| Earnings per share, diluted | 3.28 | 0.63 | 0.7 | -0.06 |
| Weighted-average common shares outstanding, basic | 17,885,000 | 17,808,000 | 17,600,000 | 17,549,000 |
| Weighted-average shares outstanding and common stock equivalents | 18,162,000 | 18,169,000 | 17,648,000 | 17,549,000 |